ELV

Institutional Snapshot

Elevance Health, Inc. · Healthcare · Healthcare Plans

$389.82
16.5
$84.65B

Company Profile

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other.

Institutional Mandate

  • Revenue diversification is shifting toward the Carelon segment, where the integration of pharmacy benefit management and clinical services is successfully decoupling earnings growth from the volatility of government-sponsored Medicaid enrollment cycles.
  • The company maintains a structural moat via its Blue Cross Blue Shield licensing footprint, which provides unmatched local market penetration and regulatory leverage that pure-play national insurers cannot replicate.
  • Capital allocation remains disciplined, with a consistent track record of utilizing excess cash flow for strategic tuck-in acquisitions in the specialty pharmacy space and aggressive share repurchases that offset dilution from long-term incentive plans.
Key Risk

The primary vulnerability lies in the 'medical loss ratio' (MLR) sensitivity to rising utilization trends in the Medicare Advantage segment, where current pricing models may fail to account for the accelerated acuity levels observed in the post-pandemic patient cohort.

Management Tone

Management maintains a disciplined, value-oriented posture, emphasizing the long-term margin expansion potential of the Carelon ecosystem over short-term enrollment volume targets.

Sector Positioning

Trading at a 1.42 PEG ratio, ELV currently commands a valuation premium relative to the broader managed care peer group, reflecting investor confidence in its integrated services model.

Deploy the proprietary analytical pipeline for ELV

Our systems have flagged ELV for structural analysis. Run the full quantitative teardown to see price targets, scenario modeling, and conviction scores.

✦ No credit card required

Short Term
BULLISH
Medium Term
NEUTRAL
Long Term
BEARISH
Intrinsic Value
$284.12
Implied Growth
18.4%
Margin of Safety
12.5%